Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
NCT ID: NCT02174432
Last Updated: 2025-05-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
36 participants
INTERVENTIONAL
2015-08-15
2017-09-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
NCT02174419
Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function
NCT02268448
RN624 For Pain Of Post-Herpetic Neuralgia
NCT00568321
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia
NCT01748877
PRISM Study-Pruritus Relief Through Itch Scratch Modulation
NCT03497975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nalbuphine HCl ER
nalbuphine HCl ER
nalbuphine HCl ER
nalbuphine HCl ER BID for up to 50 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nalbuphine HCl ER
nalbuphine HCl ER BID for up to 50 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subject is a pregnant or lactating female
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trevi Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chief Development Officer
Role: STUDY_DIRECTOR
Trevi Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Münster
Münster, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-005628-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
TR03ext
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.